promptsyndicate.ai GenAI-powered platform built for a 2030 world — where smartphones are the new printing press
Warren Peters, MD, MPH, FOMA Director – Metabolic Obesity Research Clinic (MORC) Associate Professor LOMA LINDA UNIVERSITY – School of Public Health
Read More »Research
New Approach in Parkinson’s
LRRK2 PROTAC (ARV-102): From Target Degradation to Biomarker-Driven Trials LRRK2 PROTAC (ARV-102): From Target Degradation to Biomarker-Driven Trials Curator: Warren Peters, MD, MPH, FOMA Silo: Voice of Health – Research Edition Research Summary ARV-102 is a proteolysis-targeting chimera (PROTAC) that binds LRRK2 and recruits an E3 ligase, tagging the protein for degradation. Unlike traditional kinase inhibitors, it reduces the total …
Read More »Removing a Problem Protein
A New Approach in Parkinson’s: Removing a Problem Protein (LRRK2) A New Approach in Parkinson’s: Removing a Problem Protein Silo: Voice of Health – Patient Edition What’s Being Studied Scientists are testing a new therapy called ARV-102. It helps cells identify and remove a protein called LRRK2 that may contribute to Parkinson’s. The first trial involved healthy adults to make …
Read More »What the GLP-1 Shift Means
Healthspan Is Becoming Real: What the GLP-1 Shift Means Healthspan Is Becoming Real: What the GLP-1 Shift Means At a leading aging research meeting, major drug makers described GLP-1 medicines as “longevity therapeutics.” That language shift matters: it opens the door to earlier prevention trials, better biomarkers, and treatments that aim to help us live not only longer, but better. …
Read More »GLP-1 Trial Maintains Motor Function in Parkinson’s Disease
Citation: Athauda D et al., 2025, New England Journal of Medicine, DOI 10.1056/NEJMoa2306791Research Summary:A randomized double-blind Phase 2 trial evaluated lixisenatide, a GLP-1 receptor agonist, in 156 individuals Participants received lixisenatide or placebo over 12 months. The lixisenatide group maintained stable with a decline in the placebo group. Gastrointestinal effects were the most common adverse events. Motor after treatment ended.Clinical …
Read More »Harnessing Team Science
Team Science for Dementia: The ADRC Circular Loop (Discovery → Development → Delivery → Dissemination) Harnessing Team Science in Dementia Research: The ADRC Circular Loop Citation: Akter S, Bawa EM, Riccardi N, et al. Journal of Alzheimer’s Disease Reports. 2025;9. doi:10.1177/25424823251385902 Curator: Warren Peters, MD MPH FOMA • Silo: Voice of Health (Research Edition) SEO title (≤60): Team Science for …
Read More »The Broader Context of Drug Repurposing
Introduction: Shifting the Paradigm in Alzheimer’s Research The landscape of Alzheimer’s disease (AD) research is undergoing a significant transformation. For decades, the focus has been on the amyloid hypothesis, with a multitude of clinical trials targeting amyloid-beta plaques, often with disappointing results. However, recent developments, including the NIA’s strategic funding of novel approaches, signal a new era. The award of …
Read More »Gait Variability in Parkinson’s Disease: A Researcher White Paper (2022–2025)
Executive Summary Gait variability—particularly stride-time variability (STV) and stride-length variability—has emerged as a promising but context-dependent digital signal for Parkinson’s disease (PD). Across recent studies, STV is repeatedly sensitive to disease state and intervention effects, yet its interpretability hinges on speed control, environment (overground vs treadmill), fatigue, footwear, and surface. Real-world, continuous measurement via wearables is accelerating, and combining gait …
Read More »